08 June 2023
As the deputy of Russian Minister of Health Sergey Glagolev says that there is no significant decrease in the number of applications for clinical trials from foreign pharmaceutical companies, despite the fact that numerous manufacturers have withdrawn their applications or terminated the trials that have been started. In addition, there is an increased interest in conducting clinical trials from Russian companies.
“Lately we have seen the unconstructive position of some foreign drug manufacturers by stopping the submission of applications for multicenter clinical trials. Despite such actions, a significant part of foreign companies continue to apply for these permissions,” he said during the XXV All-Russian Conference “PharmMedAppeal-2023”.
Speaking about applications coming from Russian pharmaceutical companies, Glagolev noted that “our industry is starting to explore the cutting edge, such as using orphan drugs in particular”. He also recalled that amendments to the legislation are currently being prepared to be allowed recognition of foreign clinical trials in some cases.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Long-term potential revealed for novel modifier gene therapy
21 January 2025
Binnopharm Group opened an office in Vietnam
21 January 2025
New guidance to aid cost-effectiveness analysis of new drugs
20 January 2025
The Ministry of Health may expand its patent use powers
20 January 2025